Join to View Full Profile
Orlando Health Cancer Institute1414 Kuhl AveOrlando, FL 32806
Dr. Moroose is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ConnecticutFellowship, Hematology and Medical Oncology, 1983 - 1986- University of ConnecticutResidency, Internal Medicine, 1981 - 1983
University of MarylandInternship, Internal Medicine, 1980 - 1981- Uconn School Of MedicineClass of 1980
Certifications & Licensure
FL State Medical License 1986 - 2027
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification MEDSEEK Empower, SymphonyCare, LLC, 2013-2017
- CMS Meaningful Use Stage Stage 2 Certification AllScripts FollowMyHealth®, Allscripts, 2013-2017
- CMS Meaningful Use Stage Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017
Clinical Trials
- Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 Apr 01
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
- Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Publications & Presentations
PubMed
- 3 citationsRibociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.Peter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, John Crown
JAMA Oncology. 2025-11-01 - 173 citationsRibociclib plus Endocrine Therapy in Early Breast Cancer.Dennis Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas McAndrew, Bozena Kukielka-Budny
The New England Journal of Medicine. 2024-03-21 - 70 citationsRationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapyendocrine therapy alone in patients with HR+/HER2- early breast cancer.Dennis J Slamon, Peter A Fasching, Sara Hurvitz, Stephen Chia, John Crown
Therapeutic Advances in Medical Oncology. 2023-01-01
Press Mentions
The Importance of Testing for Breast CancerDecember 11th, 2021- Breast Cancer: What Every Woman Should KnowDecember 1st, 2021
When Breast Cancer Strikes Under 40October 12th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
